Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
3,765 adverse event reports (+24% vs 2023)
In 2024, 3,765 adverse event reports were filed for RSV (Arexvy) in VAERS. This represents 40.4% of all 9,330 reports for this vaccine.
Of these reports, 36 mentioned death, 257 involved hospitalization, 279 required ER visits, and 71 reported disability.
Compared to the average of 2,941 reports per year for this vaccine, 2024 was above average (+28%).
In 2024, reporting for RSV (Arexvy) was within typical ranges. As always, VAERS data reflects reports filed, not confirmed adverse events. Trends should be interpreted alongside vaccination volume and population health data.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.